These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25278593)

  • 1. The littlest patient.
    Couzin-Frankel J
    Science; 2014 Oct; 346(6205):24-7. PubMed ID: 25278593
    [No Abstract]   [Full Text] [Related]  

  • 2. Autophagy, p53, and pancreatic cancer.
    Iacobuzio-Donahue CA; Herman JM
    N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
    [No Abstract]   [Full Text] [Related]  

  • 3. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.
    Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y
    Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Ponz-Sarvise M; Tuveson DA; Yu KH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic aspects of pancreatic cancer].
    Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
    Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.
    Xu W; Wang Z; Zhang W; Qian K; Li H; Kong D; Li Y; Tang Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):613-27. PubMed ID: 25305448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 12. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of pancreatic cancer targeting the K-Ras oncogene.
    Lisiansky V; Naumov I; Shapira S; Kazanov D; Starr A; Arber N; Kraus S
    Cancer Gene Ther; 2012 Dec; 19(12):862-9. PubMed ID: 23099885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 19. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What we have learned about pancreatic cancer from mouse models.
    Pérez-Mancera PA; Guerra C; Barbacid M; Tuveson DA
    Gastroenterology; 2012 May; 142(5):1079-92. PubMed ID: 22406637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.